David Illescas
Clinical Investigator Arrixaca University Hospital
Seminars
Monday 8th March 2027
ADCs in Ovarian Cancer: From Platinum Resistant Disease Towards Earlier Lines & Combinations
10:00 am
- What does the phase II/III dataset tell us about ADC efficacy and tolerability in ovarian cancer?
- Moving into earlier lines and combinations: Implications for trial design and patient selection
- Delving into site-level lessons on recruitment, biomarker screening and safety management
Monday 8th March 2027
Panel Discussion: Dual Payload & Novel ADCs – Balancing Enhanced Efficacy Against Overlapping Toxicities & Strategies for Effective Translation in Models & in the Clinic
1:30 pm
- How can multiple payloads overcome tumour heterogeneity, resistance, and enhance anti-tumour efficacy?
- Discussing the strategies to mitigate overlapping toxicities, optimise therapeutic windows, and balance increased potency with safety profiles through development
- Examining how preclinical models, biomarker strategies, and translational approaches can better predict clinical outcomes and support the successful development of advanced ADC formats in the clinic
